Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Clusters of protein linked to cancer warp cell membranes

Supercomputer simulations have shown that clusters of a protein linked to cancer warp cell membranes, according to scientists at The University of Texas Health Science Center at Houston (UTHealth) Medical School.

24 Jun 2014

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, today announced it has entered into a collaboration with Bayer HealthCare (Bayer) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

23 Jun 2014

Peakdale Molecular reports significant growth in demand for its medicinal chemistry services

Peakdale Molecular, a leading UK provider of medicinal chemistry and chemistry services, is celebrating its most successful year ever for revenues and earnings since the company’s inception in 1992.

19 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

18 Jun 2014

Computer programming language automates "laboratory-on-a-chip", may reduce healthcare cost

A research team at the University of California, Riverside has created a computer programming language that will automate "laboratory-on-a-chip" technologies used in DNA sequencing, drug discovery, virus detection and other biomedical applications.

17 Jun 2014

Distribution partnership announced by Nanion Technologies and Axion Biosystems

Nanion Technologies, a leading provider of automated patch clamp platforms, and Axion Biosystems, originator of the first high throughput microelectrode array system, today announce a distribution partnership in Europe and China. Nanion will immediately carry Axion’s MEA-products, supporting a broad range of biomedical applications.

17 Jun 2014

Study of human embryonic stems cells identifies bottlenecks restricting formation of colonies

A time-lapse study of human embryonic stems cells has identified bottlenecks restricting the formation of colonies, a discovery that could lead to improvement in their use in regenerative medicine.

13 Jun 2014

High-volume deep well plates available from Porvair Sciences

Precisely manufactured to SLAS/ANSI specifications - Porvair Sciences 24-well deep well plates permit users to simply undertake multiple, high volume (10ml / well) experiments in a single unit maximising both productivity and operational flexibility.

From Chromatrap® - Porvair Sciences Ltd 12 Jun 2014

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

9 Jun 2014

Research finding paves way for targeted approaches to treating cancer patients

Twelve years ago, UNC School of Medicine researcher Brian Strahl, PhD, found that a protein called Set2 plays a role in how yeast genes are expressed - specifically how DNA gets transcribed into messenger RNA. Now his lab has found that Set2 is also a major player in DNA repair, a complicated and crucial process that can lead to the development of cancer cells if the repair goes wrong.

9 Jun 2014

Scientists identify new way to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection.

6 Jun 2014

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington's disease (HD) using structural and chemical biology In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

Researchers reveal potential new drug target for dementia

Researchers at King's College London have discovered how a molecular 'scaffold' which allows key parts of cells to interact, comes apart in dementia and motor neuron disease, revealing a potential new target for drug discovery.

4 Jun 2014

Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

Bristol-Myers Squibb and Syngene International, India's largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.

3 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

Drug Discovery News and Research

Further Reading

Clusters of protein linked to cancer warp cell membranes

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Peakdale Molecular reports significant growth in demand for its medicinal chemistry services

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Computer programming language automates "laboratory-on-a-chip", may reduce healthcare cost

Distribution partnership announced by Nanion Technologies and Axion Biosystems

Study of human embryonic stems cells identifies bottlenecks restricting formation of colonies

High-volume deep well plates available from Porvair Sciences

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Research finding paves way for targeted approaches to treating cancer patients

Scientists identify new way to reactivate latent HIV

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Researchers reveal potential new drug target for dementia

Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Endo International subsidiary sells pharmaceutical drug discovery platform to AsanaBioSciences

New 5-layer flask enhances cell culture production

UNC researchers find new enzyme target for treating chronic pain

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News